



ACTAS Derma-Sifiliográficas

Full English text available at
www.actasdermo.org



REVIEW

Vitamin D and the Skin: A Review for Dermatologists[☆]



F.J. Navarro-Triviño,^{a,*} S. Arias-Santiago,^b Y. Gilaberte-Calzada^c

^a Unidad de Dermatología Médico-Quirúrgica y Venereología, Hospital Comarcal Alcalá la Real, Jaén, Spain

^b Unidad de Gestión Clínica de Dermatología y Venereología, Hospital Universitario Virgen de las Nieves, Granada, Spain

^c Servicio de Dermatología, Hospital Universitario Miguel Servet, IIS Aragón, Zaragoza, Spain

Received 19 March 2018; accepted 2 August 2018

Available online 18 April 2019

KEYWORDS

Vitamin D;
Lupus erythematosus;
Ichthyosis;
Atopic dermatitis;
Hidradenitis
suppurativa;
Acne;
Alopecia;
Melanoma

PALABRAS CLAVE

Vitamina D;
Lupus eritematoso;
Ictiosis;
Dermatitis atópica;
Hidrosadenitis
supurativa;
Acné;
Alopecia;
Melanoma

Abstract In recent years, the growing interest in the role played by vitamin D in skin disease has given rise to the publication of many studies of the relationship between this vitamin and certain skin conditions. As dermatologists, we need to understand, among other aspects, how vitamin D is synthesized and the main sources in humans, as well as plasma levels and the factors that can modify them. Of particular interest are the latest discoveries about the role of vitamin D in skin diseases such as lupus erythematosus, ichthyosis, atopic dermatitis, hidradenitis suppurativa, acne, alopecia areata, androgenetic alopecia, melanoma, and nonmelanoma skin cancer. Also of interest is the importance of vitamin D as adjuvant therapy in patients on long-term treatment with corticosteroids. In this review, we provide an overview of the most important and most recent information regarding the relationship between vitamin D and skin disease and discuss the importance of assessing individual vitamin D status and correcting deficiencies.

© 2018 Elsevier España, S.L.U. and AEDV. Published by Elsevier España, S.L.U. All rights reserved.

Vitamina D y la piel. Una revisión para dermatólogos

Resumen El papel de la vitamina D en enfermedades cutáneas ha cobrado interés en los últimos años. La relación entre esta vitamina y algunas dermatosis ha supuesto la publicación de múltiples trabajos al respecto. Como dermatólogos, conocer sus principales fuentes, síntesis, niveles plasmáticos y algunos de los factores modificadores son varios de los aspectos a recordar. Asimismo, es preciso resaltar los últimos descubrimientos sobre el papel de la vitamina D en las diferentes enfermedades dermatológicas, como el lupus eritematoso, la ictiosis, la dermatitis atópica, la hidrosadenitis supurativa, el acné, la alopecia areata y androgenética, el melanoma y el cáncer cutáneo no melanoma, así como la relevancia como terapia adyuvante en pacientes

[☆] Please cite this article as: Navarro-Triviño FJ, Arias-Santiago S, Gilaberte-Calzada Y. Vitamina D y la piel. Una revisión para dermatólogos. Actas Dermosifiliogr. 2019;110:262–272.

* Corresponding author.

E-mail address: fntmed@gmail.com (F.J. Navarro-Triviño).

en tratamiento crónico con corticoides. Acercamos al lector la información más relevante y reciente de la relación entre la vitamina D y las enfermedades de la piel, así como la importancia de conocer los niveles de esta vitamina.

© 2018 Elsevier España, S.L.U. y AEDV. Publicado por Elsevier España, S.L.U. Todos los derechos reservados.

Background

Rickets, a condition caused by vitamin D deficiency, was first described by Glisson, DeBoot and Whistler in the seventeenth century. Subsequently, in 1882, Sniadecki realized the importance of exposure to sunlight for the prevention and cure of rickets. Today, we know that the role of vitamin D in the body goes beyond the regulation of bone mineral metabolism, making the function of this vitamin important to a wide range of medical specialists. Charpy¹ published the first study linking vitamin D levels and lupus vulgaris in 1945. In 2016, Deschasaux et al.² published the results of a study based on an online questionnaire designed to investigate the understanding of the role of vitamin D in the general population. They reported that over 1-third of the respondents were unaware of the role of vitamin D in the body—a significant finding in light of the fact that vitamin D levels were insufficient in 40% of a subsample of respondents in whom these were tested. The recent literature includes several interesting new studies linking vitamin D levels with a number of common skin disorders. The aim of the present review is to provide an overview of the relationship between vitamin D and skin disease based on current evidence.

Synthesis

The body obtains vitamin D in two ways. A small amount of active vitamin D in the form of cholecalciferol can be obtained from dietary intake of animal origin: the foods with significant levels are egg yolks and certain blue fish (Table 1). Ergocalciferol, another form of pre-vitamin D, is found in small amounts in foods of vegetable origin. The

other way the body obtains vitamin D is through exposure to solar radiation. Photons in UV-B radiation photo-isomerize 7-dehydrocholesterol in the epidermis to precholecalciferol, which is then rapidly converted through a heat-mediated reaction to cholecalciferol or vitamin D₃. Both molecules are hydroxylated in the liver to calcifediol (25-hydroxyvitamin D [25(OH)D]), which is later hydroxylated in the kidneys through the action of the enzyme 25(OH)D-1-hydroxylase to calcitriol, the active metabolite that performs a range of different functions by binding to its cell receptor. Parathyroid hormone (PTH), calcium, and phosphorus levels are just some of the factors that play a role in the regulation of this process, in addition to transforming growth factor beta (Fig. 1).

Vitamin D Levels and Vitamin D Deficiency. Is There Really a Pandemic?

Daily vitamin D requirements are age dependent and different medical associations do not agree on the levels required. According to the Institute of Medicine (IoM), the daily requirement is 400 IU in the first year of life, 600 IU between 12 months and 70 years of age, and 800 IU in people over 70 years of age.³ However, the American Endocrine Society recommends between 400 and 1000 IU/d in the first year of life and 600 to 1000 IU/d thereafter.

In 2009, 25(OH)D was established as the best blood marker of vitamin D status.⁴ The societies also have different opinions about desirable levels in the body. While the IoM specifies 20 ng/mL as the lower limit indicating healthy and sufficient levels of vitamin D (Appendix A), the American Endocrine Society defines a level under 20 ng/mL as deficient and a level between 20 and 30 ng/mL as insufficient, and considers values above 30 ng/mL (75 nmol/L) to be essential for maintaining good health.⁵ There is currently generalized alarm worldwide about vitamin D deficiency in both the healthy and the sick population. In response to this situation, an article in *The New England Journal of Medicine* addressed the question of whether or not there is really a pandemic of vitamin D deficiency in the world today.⁶ Between 35% and 70% of Europeans have 25 (OH) D levels considered insufficient by some authors.⁷ By contrast, in Australia and New Zealand, the percentage ranges from 6% to 9%. Publication of these findings might lead to the consideration of the usefulness of screening healthy people for vitamin D deficiency. However, since routine screening is not currently supported by the IoM or the US Preventive Services Task Force, it is not recommended at this time.

Vitamin D toxicity can cause serious health problems. Blood levels persistently above 200 ng/mL are considered

Table 1 Foods Rich in Vitamin D.

Food	IU per Serving
Cod liver oil (5 mL)	1360
Salmon (100 g)	360
Mackerel (100 g)	345
Sardines in oil (100 g)	500
Tuna in oil (100 g)	238
Fortified milk (250 mL)	115-124
Fortified orange juice (250 mL)	100
Fortified yoghurt (1.5 L)	80
Margarine (5 mL)	60
Cereals (fortified) (250 mL)	40
Eggs (1)	25
Cheese (28 g)	6-12

Source: Gilaberte et al.¹⁵




Figure 1 Vitamin D Metabolism. The body acquires vitamin D from certain foods and through a reaction that occurs when the skin is exposed to sunlight in which UV-B radiation converts 7-dehydrocholesterol (synthesized in the skin) to pre-vitamin D₃, which then becomes inactive vitamin D. This is then converted in the liver to 25(OH)D by way of hepatic hydroxylation. In a second step, 25(OH)D is metabolized in the kidney to the active metabolite 1,25(OH)D, or calcitriol, through the action of renal alpha-1-hydroxylase. This mechanism is regulated by serum levels of calcium and inorganic phosphorus, among others, which are detected by the glands that secrete parathyroid hormone (PTH) and stimulate the activity of alpha-1-hydroxylase, when necessary. Calcitriol concentrations regulate the secretion of PTH. The 1,25(OH)D acts through the vitamin D receptors (VDR) within cells, which activate the transcription and translation of messenger RNA, leading to the synthesis of vitamin D-dependent proteins and their corresponding activity, which depend on the function of the target cell. The excretion of vitamin D through bile is mediated by the activity of 24 renal hydroxylase, which converts 1,25(OH)D to calcitroic acid.

toxic. The most frequent symptoms of toxicity are anorexia, weight loss, polyuria, and cardiac arrhythmias. Vitamin D toxicity also increases the risk of kidney stone formation, the calcification of blood vessels and tissues, and the complications associated with both of these alterations. Toxicity can occur when the daily intake of vitamin D exceeds 10,000 IU, giving rise to 25(OH)D levels in excess of 200 to 240 ng/mL. However, most medical societies consider 25(OH)D levels higher than 125 to 150 ng/mL to be unadvisable in order to avoid the adverse effects of a vitamin D excess.

Modifying Factors

Some people are more susceptible than others to developing vitamin D deficiency, defined as a level below the established minimum of 20 ng/mL (Table 2). Risk factors for susceptibility include obesity,⁸ smoking,⁹ a high skin phototype¹⁰ (although this is still controversial), insufficient sun exposure, and age.¹¹ With age, the skin produces less of the precursor 7-dehydrocholesterol in the epidermis, intestinal absorption of vitamin D declines due to a reduction in the number of vitamin D receptors (VDR) in enterocytes, and the body's ability to hydroxylate vitamin D in the liver and kidney also decreases. Some clinical conditions predispose patients to inadequate vitamin D levels.¹² These include osteoporosis, chronic kidney disease, liver failure, inflammatory bowel disease,

Table 2 Risk Factors Associated with Low Vitamin D Levels.

Risk Factors for Hypovitaminosis D

Inadequate exposure to sunlight (controversial)
 Smoking
 Obesity
 High skin phototype (IV or greater)
 Older age
 Institutionalization
 Current treatment with corticosteroids, antiepileptics, hormone therapies for breast or prostate cancer, immunosuppressants, or antiretrovirals
 History of osteoporosis
 Chronic kidney disease
 Liver failure
 Inflammatory bowel disease
 Hyperparathyroidism
 Hypogonadism
 Celiac disease

hyperparathyroidism, hyperthyroidism, hypogonadism, and celiac disease. Another risk factor is long-term treatment with certain drugs, including anticonvulsants, antiretrovirals, rifampicin, hormonal treatments prescribed for breast and prostate cancer, and, above all, corticosteroids. Pregnancy can also give rise to low 25(OH)D levels.

Table 3 Functions of Vitamin D in the Body.**Functions of Vitamin D**

Role in bone mineral metabolism.

Role in the control of carcinogenesis and metastasis. Inhibits proliferation, stimulates differentiation, promotes apoptosis, inhibits angiogenesis, and contributes to DNA repair.

Blood sugar regulation. Regulates insulin secretion in the pancreas and decreases peripheral insulin resistance.

Lipid synthesis regulation.

Regulation of blood pressure through its effects on the renin-angiotensin-aldosterone system. Inhibits renin expression in the kidneys.

Stimulates the synthesis of nitric oxide in the cardiovascular system.

Immunomodulatory effect in keratinocytes. Regulates initial stages of proliferation and differentiation.

Regulates the growth cycle of hair follicles.

Regulates innate and adaptive pathways of the immune system. Participates in the proliferation and activation of dendritic cells, regulates the activation of CD4 lymphocytes, reduces the formation of T helper (Th) 1-9-17 cells, and promotes differentiation of Th2 and T regulators. Plays a role in the activation of selective Toll-like receptors (TLR 1/2)

Functions of Vitamin D: Regulation of Bone Metabolism and Other Pleiotropes

In 2016, Bikle¹³ described the principal functions of vitamin D in the body. A more recent article discussed the relationship between vitamin D and the skin.¹⁴ Vitamin D has been shown to have antiproliferative properties, including the inhibition of angiogenesis and metastatic capacity in some tumors, and it also participates in DNA repair. A relationship has even been found between certain mutations in the VDR gene and cancer. In the metabolic system, vitamin D plays an important role in glucidic, lipid, arterial, and vascular homeostasis. It also modulates immune responses by regulating the differentiation of T helper (Th) 1-9-17 cells and by inducing the formation of antimicrobial peptides such as cathelicidin peptides. In dermatology, it is important because of its immunomodulatory effects in keratinocytes, as described by Gilaberte et al.¹⁵ Vitamin D plays an important role in the homeostasis of glucose by promoting insulin secretion in pancreatic beta cells,¹⁶ which express alpha-1-hydroxylase through cell stimulation by way of high affinity VDR. Moreover, it decreases peripheral insulin resistance by activating peroxisome proliferator-activated gamma receptors in the liver, muscle, and fatty tissue. In view of this relationship, it has been postulated that vitamin D may be a protective factor in the development of type 2 diabetes mellitus.¹⁷ In the case of lipid metabolism, vitamin D can also have an indirect effect, not only because it may improve peripheral insulin resistance¹⁸ and reduce PTH levels (shown to have a lipolytic effect),¹⁹ but also because it favors higher serum calcium levels, thereby decreasing hepatic triglyceride production.²⁰ In 2010, Pittas et al.²¹ published a systematic review on the relationship between blood pressure and vitamin D levels. Their conclusion was that deficient vitamin D levels (< 20 ng/mL) were associated with an increased risk of arterial hypertension. Other studies have shown that vitamin D supplementation improved blood pressure in hypertensive patients.²² This improvement is mediated by various effects: direct effects on vitamin D receptors, which decrease vascular inflammation and correct endothelial dysfunction; regulation of the proliferation, migration, and

mineralization of vascular muscle cells²³; and finally, indirectly by decreasing serum levels of PTH, a hormone that acts on the renin-angiotensin-aldosterone system. Furthermore, recent studies have shown that vitamin D stimulates the release of nitric oxide, thereby reducing oxidative stress in the cardiovascular system.²⁴ It is, therefore, clear that vitamin D not only plays a role in bone metabolism but is also involved in many other functions in the body (Table 3).

Vitamin D and Skin Disease

Vitamin D has been implicated in the pathogenesis and treatment of a wide variety of skin diseases. These are discussed below.

Psoriasis

Krafka²⁵ and Thacker²⁶ were the first scientists to postulate a role for vitamin D in psoriasis. The use of oral vitamin D as a treatment for psoriasis failed because of the risk of hypercalcemia. The development of topical vitamin D analogs, such as calcipotriol and tacalcitol, later revolutionized the treatment of the condition. Bergler-Czop and Brzezińska-Wcisło²⁷ observed a correlation between Psoriasis Area and Severity Index (PASI) scores and serum levels of 25(OH)D and reported that patients with lower vitamin D levels had higher PASI scores. Orgaz-Molina et al.²⁸ demonstrated that patients with psoriasis and a body mass index higher than 27 were more likely to have insufficient 25(OH)D levels. The comorbidities of psoriasis (diabetes mellitus, obesity, and metabolic syndrome) have also been linked to diets low in vitamin D.²⁹ Clinicians should recommend diets that provide vitamin D in view of its beneficial effect on many of the comorbidities associated with psoriasis. The use of vitamin D in psoriasis is currently a grade B recommendation with IIa level of evidence.

Atopic Dermatitis

Atopic dermatitis (AD) is a chronic and recurrent inflammatory disease, initially characterized by pruritus and

eczematous lesions. It affects up to 20% of the pediatric population and around 7.2% of adults.³⁰ AD is caused by an alteration in the cutaneous immune system and a defect in the synthesis of the epidermal barrier, which affects mainly filaggrin.^{31,32} Many authors have studied the association between vitamin D and AD. Kim et al.³³ published a meta-analysis and systematic review of 11 articles, 7 observational studies, and 4 clinical trials. Compared to healthy controls, patients with AD had lower levels of vitamin D, especially in the pediatric population. Oral vitamin D supplements have been associated with reductions in SCORAD and Eczema Area and Severity Index scores in pediatric patients and is considered to be a possible adjuvant treatment in patients with a deficiency (levels below 20 ng/mL). In a series of 210 adult patients with AD, Van der Schaft et al.³⁴ reported that vitamin D supplementation in patients with deficient levels did not lead to any significant improvement in eczematous lesions. Several studies in the literature report that vitamin D supplementation in children decreased colonization with *Staphylococcus aureus*, a microorganism that plays a role in outbreaks of DA.³⁵⁻³⁷ Despite the evidence that vitamin D levels tend to be insufficient in adult patients with AD,³⁸ there is still debate about whether vitamin D supplementation is useful in this age group. In children the use of vitamin D is a grade B recommendation with a IIa level of evidence.

Ichthyosis Congenita

Sethuraman et al.³⁹ reported low levels of 25(OH)D and high levels of PTH in children with ichthyosis congenita. In that study, vitamin D supplementation with 60,000 IU of oral cholecalciferol for 10 days followed by a maintenance regimen of 400 to 600 IU/d achieved a rapid response, with noticeable improvement in the dermatological symptoms by the fifth day in terms of both scaling and stiffness. Of the 7 children studied, 6 had serum 25(OH)D levels under 4 ng/mL. While more studies are needed, these findings open up interesting possibilities in the management of ichthyosis congenita. Lucker et al.⁴⁰ published the results achieved with topical calcipotriol in patients with ichthyosis congenita (Netherton syndrome, lamellar, ichthyosis bullosa of Siemens, and epidermolytic ichthyosis of Brocq). Scaling and associated redness improved in all but the bullous form of the disease. In ichthyoses in which epidermal hyperproliferation and retention hyperkeratosis do not predominate—such as X-linked ichthyosis, ichthyosis vulgaris, and acquired ichthyosis—topical application of vitamin D analogs has not been shown to be effective.⁴¹ Neema et al.⁴² raised the possibility of combining vitamin D with oral retinoid treatment in patients with low vitamin D levels. Despite the published findings, the use of vitamin D supplementation in patients with ichthyosis is a grade C recommendation with a IIIa level of evidence.

Acne

Interest in the role of vitamin D in acne first emerged in 1938.⁴³ A comparative study of serum levels of 25(OH)D in adolescents with and without acne was published in PLoS One in 2016.⁴⁴ The patients with acne had lower

vitamin D levels than the healthy controls and an inverse relationship was observed between vitamin D levels and the severity and number of inflammatory acne lesions. Following 2 months of vitamin D supplementation, the number of inflammatory lesions decreased but no change was observed in non-inflammatory lesions. The role of vitamin D in acne could be explained by a relationship between the vitamin and reduced synthesis of interleukin (IL) 6, IL-8 and metalloproteinase-9⁴⁵ as well as to a reduction in the expression of IL-17 because of its action on Th17 cells.⁴⁶ Zouboulis et al.⁴⁷ described the effect of vitamin D on the sebaceous glands and the increase in lipogenesis when vitamin D levels are insufficient, an effect that promotes an increase in inflammatory lesions. The authors of a recent study reported that 25(OH)D levels were higher following treatment than at baseline in patients treated with oral isotretinoin, concluding that the role of vitamin D in the inflammatory pathogenesis of acne is important in the development of lesions.⁴⁸ The use of vitamin D in acne is currently a grade B recommendation with a IIb level of evidence.

Hidradenitis Suppurativa

Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with a significant impact on the patients' quality of life. Several studies have been published on the relationship between HS and vitamin D levels.^{49,50} In those studies, the patients with HS had lower vitamin D levels than controls and an inverse correlation was observed between vitamin D levels and disease severity. Following 6 months of vitamin D supplementation, inflammatory nodules improved in 79% of patients (out of the 14 treated); however, as with acne, no significant changes were observed in non-inflammatory lesions. In the opinion of the authors of another study, the endocrinological and metabolic alterations associated with HS make vitamin D a therapeutic target because of its relationship with metabolic syndrome, among other reasons.⁵¹ Well-designed studies with a sufficient number of patients are needed to determine the role of vitamin D in HS. The use of vitamin D in HS is currently a grade B recommendation with a III level of evidence.

Vitiligo

There are more than 300 articles in the literature on the relationship between vitamin D and vitiligo. Karagün et al.⁵² observed lower serum vitamin D levels in 50 patients with vitiligo compared to healthy controls and an inverse correlation with the extent of disease. In a meta-analysis, Upala and Sanguankee⁵³ concluded that the evidence did indicate a clear relationship between vitiligo and low vitamin D levels. Variable results have been reported in cases in which vitiligo was treated with vitamin D analogs either alone⁵⁴ or in combination with other treatments.⁵⁵ However, there are no clinical trials that demonstrate the efficacy of vitamin D supplements in these patients. Khurram and AlGhamdi⁵⁶ found no significant differences in vitamin D levels between patients with vitiligo and healthy controls; in the analysis by subgroups, however, it was observed that in the group of patients with vitiligo, the lowest vitamin D levels were

associated with male sex, younger age, a short duration of vitiligo, and not having received treatment with phototherapy. At present, the use of vitamin D in patients with vitiligo is a grade B recommendation with a IIa level of evidence.

Systemic Lupus Erythematosus

Several studies have found a higher prevalence of vitamin D deficiency in patients with systemic lupus erythematosus (SLE) than in the healthy population.^{57,58} The authors of a study published in PLoS One, which investigated the relationship between vitamin D levels and the severity of SLE, reported that 71.4% of the patients had vitamin D levels under 30 ng/mL.⁵⁹ They also observed an association between lower vitamin D levels and poorer scores on the Systemic Lupus Erythematosus Disease Activity Index. However, supplementation with 400 to 1,000 IU/d of vitamin D failed to raise levels above 30 ng/mL. In a comparative study with placebo by Karimzadeh et al.,⁶⁰ patients with SLE who received vitamin D supplementation showed a significant increase in serum 25(OH)D levels but this was not associated with any effect on disease activity. Some authors defend the usefulness of vitamin D supplementation in these patients on the basis of the protective cardiovascular effect and the possible improvement in systemic symptoms and cognitive development.⁶¹ The authors of a recent review article on this topic defend the usefulness of vitamin D in SLE on the basis of its immunomodulatory effects.⁶² The use of vitamin D in patients with SLE is a grade B recommendation with a IIa evidence level.

Polymorphic Light Eruption

Polymorphic light eruption (PLE) is an idiopathic photosensitivity disorder related primarily with exposure to UV-A and less often with UV-B radiation. It is found more frequently in young women. Schweintzger et al.⁶³ found no significant relationship between vitamin D levels and the number and function of regulatory T cells, concluding that other factors affect the immune response that occurs in PLE. Nevertheless, in another study patients with PLE had lower vitamin D levels than controls and when these were increased by phototherapy with UV-B (311 nm) a correlation was observed between the increase and clinical improvement of the lesions.⁶⁴ In a placebo-controlled clinical trial, Gruber-Wackernagel et al.⁶⁵ observed that topical application of calcipotriol 1 week before exposure reduced symptoms in almost 1-third of patients exposed to photoprovocation and suggested this treatment as a possible prophylactic measure. However, there is no consensus in photobiology units on the use of this treatment for PLE. The use of vitamin D in PLE is a grade B recommendation with a IIb level of evidence.

Alopecia Areata

The role of vitamin D in alopecia areata (AA) has been explored in several studies.^{66–69} Thompson et al.⁷⁰ analyzed data from a cohort of 55,929 women and found no association between vitamin D supplementation and incident AA.

However, other studies have found that vitamin D levels tend to be lower in patients with AA than in healthy controls⁷¹ and even lower in patients with universal AA compared to those with the ophthalmic or plaque forms. Vitamin D levels have not been shown to differ significantly according to age, sex, disease duration, disease recurrence, or family history of AA. However, patients with AA have been found to have a lower number of vitamin D receptors in the blood and tissues than the group of healthy controls.⁷²

While topical vitamin D analogs can be used to treat AA,^{72,73} no studies have been carried out which demonstrate that oral supplements with vitamin D are effective in this setting.

The use of vitamin D in patients with AA is currently a grade B recommendation with a IIb level of evidence.

Melanoma and Melanoma Metastasis

The role of vitamin D in melanoma has been investigated in a number of studies.^{74–77} Orlow et al.⁷⁸ identified certain haplotypes of single nucleotide polymorphisms (SNPs) of the vitamin D receptor gene related to increased survival in patients with melanomas in photoexposed sites (rs1544410/BsmI and rs731236/TaqI). Subsequent studies have reported an inverse correlation between Breslow thickness and vitamin D levels⁷⁹ and a possible relationship between low serum vitamin D levels and ulceration⁸⁰ in patients with melanoma. In fact, a worse prognosis was observed in the patients whose vitamin D levels were low when melanoma was diagnosed and also when, even after starting supplementation, the patient did not achieve levels above 20 ng/mL. In a recent study of 3578 patients, however, no significant relationship was found between melanoma survival, determined by the Breslow thickness, number of mitosis, ulceration, and SNPs found in the pathway of vitamin D and its receptor.⁸¹ This debate has led to new studies to determine the possible advantage of recommending vitamin D supplementation in patients with melanoma in sun-exposed and sun-shielded sites.⁸² The use of vitamin D in patients with melanoma is currently a grade B recommendation with a IIb level of evidence.

Nonmelanoma Skin Cancer

The role of vitamin D in carcinogenesis⁸³ led to the study of its relationship with nonmelanoma skin cancer (NMSC).⁸⁴ The cells of basal cell and squamous cell tumors express VDRs. Eide et al.⁸⁵ reported an association between high vitamin D levels and an increased risk of keratinocyte carcinoma. Vitamin D is also able to inhibit the Hedgehog signaling pathway in basal cell carcinoma.⁸⁶ Research has shown that patients with the BsmI SNP of the vitamin D receptor have a higher risk of developing NMSC.⁸⁷ However, in a prospective study with more than 60,000 participants, vitamin D supplementation was not associated with squamous cell carcinoma risk or the incidence of basal cell carcinoma.⁸⁸ Confounding factors such as sun exposure and phototype, among others, have given rise to controversies on this topic and clinical trials are required to gain a better understanding of the role of vitamin D in NMSC. The use of vitamin D in patients with NMSC is a grade B recommendation with a IIb level of evidence.

Table 4 Indications for Vitamin D Supplementation During Corticosteroid Therapy.

Postmenopausal women	Men and premenopausal women
Patients who are going to take or are taking over 5 mg/d of a corticosteroid for more than 3 mo Patients who have a bone mineral density T-score below -1.5 and are going to take or are taking over 2.5 mg/d of a corticosteroid for more than 3 mo	Patients who are going to take or are taking over 7.5 mg/d of a corticosteroid for more than 3 mo Patients who have a bone mineral density T-score below -1.5 and are going to take or are taking over 5 mg/d of corticosteroid for more than 3 mo All patients with a history of fractures caused by bone fragility

Table 5 Vitamin D Formulations Available in Spain.

Cholecalciferol <hr/> <i>Drops. 10 mL vial (20,000 IU): 0.05 mg = 400 IU = 6 drops</i> <i>2.5 mL oral solution (25,000 IU) equivalent to 0.625 mg</i>
Calcifediol <hr/> <i>Drop: 0.1 mg/mL (6,000 IU); 240 IU (4 µg) = 1 drop</i> <i>Liquid in ampoules:</i> 0.266 mg (16,000 IU) 3 mg (180,000 IU) <i>Soft capsules 0.266 mg (16,000 IU)</i>

Vitamin D Supplementation in Patients on Long-Term Treatment with Systemic Corticosteroids

Chronic use of systemic corticosteroids gives rise to complications, which include osteoporosis. This is due to the osteolytic activity observed in the short term, associated with osteoblast and osteocyte apoptosis in long-term treatment. The overall relative risk of fractures associated with corticosteroid treatment is 1.33. The risk is higher for vertebral fractures (RR 2.60), hip fractures (RR 1.60), and forearm or Colles fractures (RR 1.09). Associated risk factors in each patient must be taken into account; these include advanced age, family history of fracture or osteoporosis, early menopause, smoking, and a low body mass index determined by bone densitometry.⁸⁹ The usefulness of vitamin

D supplementation during prolonged treatment with oral corticosteroids is supported by the findings of a number of studies.^{90,91} A meta-analysis by Reid et al.⁹² revealed a correlation between fracture risk and deficient 25(OH)D levels. In another meta-analysis of 11 clinical trials, which included people over 65 years of age (mostly women) showed that supplementation with 800 IU/d of cholecalciferol reduced the risk of hip fracture by 30% and the risk of non-vertebral fracture by 14%, regardless of whether the patients were also taking calcium supplements.⁹³ In several studies, treatment with anti-resorptive agents, such as risedronate or alendronate, in combination with cholecalciferol supplementation for 13 months was associated with an increase in bone mineral density assessed by densitometry.^{94,95} Table 4 shows the indications for vitamin D supplementation in patients on chronic corticosteroid treatment. Table 5 shows the available forms of vitamin D supplements and Table 6 the recommended dosage according to serum vitamin D levels.

Conclusion

Vitamin D has a multiplicity of functions on the cellular level in the many organs and tissues where there are VDR. It would appear that this hormone is fundamental in dermatology, not only because it is synthesized in the skin, but also because of its multiple actions, which are reflected in the variety of diseases in which it appears to play a role. Table 7 summarizes the diseases in which serum vitamin D levels should be measured and vitamin D supplementation should be considered, depending on the results and taking into account the level of scientific evidence in each case (Table 8).

Table 6 Vitamin D Supplement Dosages According to 25(OH)D Serum Levels as Specified in the Summary of Product Characteristics.

Treatment of deficiency (10-19 ng/mL) Cholecalciferol 25,000 IU weekly for 8 wks and then every 15 d for a further 8 wks, followed by a maintenance regimen of 25,000 IU every 2-4 wks Calcifediol 16,000 IU weekly for 10 wks and monthly thereafter.
Treatment of severe deficiency (< 10 ng/mL) Cholecalciferol 25,000 IU twice weekly for 6 wks, and then 25,000 IU weekly for 4 wks, followed by a maintenance dose of 25,000 IU every 2-4 wk thereafter, depending on serum levels Shock treatment with calcifediol 3 mg (180,000 IU) in a single dose followed by 16,000 IU monthly, depending on serum levels (with a 2-month loading period)

Table 7 Skin Diseases Related to Alterations in Vitamin Levels D.

Psoriasis
Atopic dermatitis
Ichthyosis congenita
Acne
Hidradenitis suppurativa
Vitiligo
Systemic lupus erythematosus
Polymorphic light eruption
Alopecia areata
Melanoma
Nonmelanoma skin cancer

Table 8 Vitamin D Supplementation in Skin Diseases: Grades of Recommendation and Levels of Evidence.

Skin Disease	Grade of Recommendation	Level of Evidence
Psoriasis	B	Ila
Atopic dermatitis	B	Ila
Ichthyosis congenita	C	IIIa
Acne	B	Ilb
Hidradenitis suppurativa	B	III
Vitiligo	B	Ila
Systemic lupus erythematosus	B	Ilb
Polymorphic light eruption	B	Ilb
Alopecia areata	B	Ila
Melanoma	B	Ilb
Nonmelanoma skin cancer	B	Ilb

Conflicts of Interest

The authors declare that they have no conflicts of interest.

Addendum. Serum levels of 25(OH)D

nmol/L	ng/mL	Health Status
< 30	< 12	Associated with vitamin D deficiency, which causes rickets in infants and children and osteomalacia in adults
30-50	12-20	Generally considered inadequate for bone health
≥ 50	≥ 20	Generally considered appropriate for bone and general health in healthy individuals
> 125	> 50	Emerging evidence links such high levels with potential adverse effects, particularly > 150 nmol/L (> 60 ng/mL)

1 nmol/L/L equals 0.4 ng/mL.

Source: Institute of Medicine, Food and Nutrition Board.³

References

- Charpy J. A propos du traitement du lupus tuberculeux; une question de priorité. *Ann Dermatol Syphiligr.* 1945;5:317.
- Deschasaux M, Souberbielle JC, Partula V, Lécuyer L, Gonzalez R, Srour B, et al. What do people know and believe about vitamin D? *Nutrients.* 2016;8:718.
- Institute of Medicine, Food and Nutrition Board. Dietary reference intakes for calcium and vitamin D. Washington, DC: National Academy Press; 2010.
- Seamans K, Cashman K. Existing and potentially novel functional markers of vitamin D status: A systematic review. *Am J Clin Nutr.* 2009;89:1997s–2000s.
- Holick MF, Binkley NC, Bischoff-Ferrari HA, Gordon CM, Hanley DA, Heaney RP, et al., Endocrine Society. Evaluation, treatment, and prevention of vitamin D deficiency: An Endocrine Society clinical practice guideline. *J Clin Endocrinol Metab.* 2011;96:1911–30.
- Manson JE, Brannon PM, Rosen CJ, Taylor CL. Vitamin D deficiency — Is there really a pandemic? *N Engl J Med.* 2016;375:1817–20.
- Spiro A, Buttriss JL. Vitamin D: An overview of vitamin D status and intake in Europe. *Nutr Bull.* 2014;39:322–50.
- Pereira-Santos M, Costa PR, Santos CA, Santos DB, Assis AM. Obesity and vitamin D deficiency: Is there an association? *Obes Rev.* 2016;17:484.
- Mulligan JK, Nagel W, O’Connell BP, Wentzel J, Atkinson C, Schollosser RJ. Cigarette smoke exposure is associated with vitamin D3 deficiencies in patients with chronic rhinosinusitis. *J Allergy Clin Immunol.* 2014;134:342–9.
- Xiang F, Lucas R, de Gruijl F, Norval M. A systematic review of the influence of skin pigmentation on changes in the concentrations of vitamin D and 25-hydroxyvitamin D in serum following experimental UV irradiation. *Photochem Photobiol Sci.* 2015;14:2138–46.
- Working Group on Osteoporosis and Mineral Metabolism of the Spanish Society of Endocrinology Reyes-García R, García-Martín A, Varsavsky M3, Rozas-Moreno P, Cortés-Berdonces M, Luque-Fernández I, et al. Update of recommendations for evaluation and treatment of osteoporosis associated to endocrine and nutritional conditions. *Endocrinol Nutr.* 2015;62:e47–56.
- Whittier X, Saag KG. Glucocorticoid-induced osteoporosis. *Rheum Dis Clin North Am.* 2016;42:177–89.
- Bikle D. Extraskelatal actions of vitamin D. *Ann N Y Acad.* 2016;1376:29–52.
- Kechichian E, Ezzedine K. Vitamin D and the skin: An update for dermatologists. *Am J Clin Dermatol.* 2018;19:223–35.
- Gilaberte Y, Aguilera J, Carrascosa JM, Figueroa FL, Román de Gabriel J, Nagore E. La vitamina D: evidencias y controversias. *Actas Dermosifiliogr.* 2011;102:572–88.
- Song Y, Wang L, Pittas AG, del Gobbo LC, Zhang C, Manson JE, et al. Blood 25-hydroxy vitamin D levels and incident type 2 diabetes: A meta-analysis of prospective studies. *Diabetes Care.* 2013;36:1422–8.
- Inomata S, Kadowaki S, Yamatani T, Fukase M, Fujita T. Effect of 1 alpha (OH)-vitamin D3 on insulin secretion in diabetes mellitus. *Bone Miner.* 1986;1:187–92.
- Kamycheva E, Jorde R, Figenschau Y, Haug E. Insulin sensitivity in subjects with secondary hyperparathyroidism and the effect of a low serum 25-hydroxyvitamin D level on insulin sensitivity. *J Endocrinol Invest.* 2007;30:126–32.

19. Zemel MB, Shi H, Greer B, Dirienzo D, Zemel PC. Regulation of adiposity by dietary calcium. *FASEB J*. 2000;14:1132–8.
20. Zittermann A, Frisch S, Berthold HK, Götting C, Kuhn J, Kleesiek K, et al. Vitamin D supplementation enhances the beneficial effects of weight loss on cardiovascular disease risk markers. *Am J Clin Nutr*. 2009;89:1321–7.
21. Pittas AG, Joseph NA, Greenberg AS. Adipocytokines and insulin resistance. *J Clin Endocrinol Metab*. 2004;89:447–52.
22. Pfeifer M, Begerow B, Minne HW, Nachtigall D, Hansen C. Effects of a short-term vitamin D(3) and calcium supplementation on blood pressure and parathyroid hormone levels in elderly women. *J Clin Endocrinol Metab*. 2001;86:1633–7.
23. Forman JP, Scott JB, Ng K, Drake BF, Suarez EG, Hayden DL, et al. Effect of vitamin D supplementation on blood pressure in blacks. *Hypertension*. 2013;61:779–85.
24. Khan A, Dawoud H, Malinski T. Nanomedical studies of the restoration of nitric oxide/peroxynitrite balance in dysfunctional endothelium by 1,25-dihydroxy vitamin D3 — clinical implications for cardiovascular diseases. *Int J Nanomedicine*. 2018;13:455–66.
25. Krafka J, Augusta G. A simple treatment for psoriasis. *J Lab Clin Med*. 1936;21:1147–8.
26. Thacker EA. The treatment of psoriasis with various vitamin D preparations. *Illinois Med J*. 1940;78:352–60.
27. Bergler-Czop B, Brzezińska-Wcislo L. Serum vitamin D level — the effect on the clinical course of psoriasis. *Postepy Dermatol Alergol*. 2016;33:445–9.
28. Orgaz-Molina J, Buendía-Eisman A, Arrabal-Polo MA, Ruiz-Carrascosa JC, Arias-Santiago S. Deficiency of serum concentration of 25-hydroxyvitamin D in psoriatic patients: A case-control study. *J Am Acad Dermatol*. 2012;67:931–8.
29. Barrea L, Savanelli MC, Di Somma C, Napolitano M, Megna M, Colao A, et al. Vitamin D and its role in psoriasis: An overview of the dermatologist and nutritionist. *Rev Endocr Metab Disord*. 2017;18:195–205.
30. Silverberg JI. Public health burden and epidemiology of atopic dermatitis. *Dermatol Clin*. 2017;35:283–9.
31. Bieber T. Atopic dermatitis. *N Engl J Med*. 2008;358:1483–94.
32. Leung DY, Bieber T. Atopic dermatitis. *Lancet*. 2003;361:151–60.
33. Kim MJ, Kim SN, Lee YW, Choe YB. Vitamin D status and efficacy of vitamin D supplementation in atopic dermatitis: A systematic review and meta-analysis. *Nutrients*. 2016;8, piiE789.
34. Van der Schaft J, Ariens LF, Bruijnzeel-Koomen CA, de Bruin-Weller MS. Serum vitamin D status in adult patients with atopic dermatitis: Recommendations for daily practice. *J Am Acad Dermatol*. 2016;75:1257–9.
35. Hata TR, Kotol P, Jackson M, Nguyen M, Paik A, Udall D, et al. Administration of oral vitamin D induces cathelicidin production in atopic individuals. *J Allergy Clin Immunol*. 2008;122:829–31.
36. Peroni DG, Piacentini GL, Cametti E, Chinellato I, Boner AL. Correlation between serum 25-hydroxyvitamin D levels and severity of atopic dermatitis in children. *Br J Dermatol*. 2011;164:1078–82.
37. Udompataikul M, Huajai S, Chalermchai T, Taweechotipatr M, Kamanamool N. The effects of oral vitamin D supplement on atopic dermatitis: A clinical trial with *Staphylococcus aureus* colonization determination. *J Med Assoc Thai*. 2015;98 Suppl. 9:s23–30.
38. Haeck IM, Hamdy NA, Timmer-de Mik L, Lentjes EG, Verhaar HJ, Knol MJ, et al. Low bone mineral density in adult patients with moderate to severe atopic dermatitis. *Br J Dermatol*. 2009;161:1248–54.
39. Sethuraman G, Marwaha RK, Challa A, Yenamandra VK, Ramakrishnan L, Thulkar S, et al. Vitamin D: A new promising therapy for congenital ichthyosis. *Pediatrics*. 2016;137, <http://dx.doi.org/10.1542/peds.2015-1313>.
40. Luckner GP, van de Kerkhof PC, van Dijk MR, Steijlen PM. Effect of topical calcipotriol on congenital ichthyoses. *Br J Dermatol*. 1994;131:546–50.
41. Okano M. Assessment of the clinical effect of topical tacalcitol on ichthyoses with retentive hyperkeratosis. *Dermatology*. 2001;202:116–8.
42. Neema S, Mukherjee S, Vasudevan B, Verma R, Moorchung N, Chatterjee M. Vitamin D deficiency after oral retinoid therapy for ichthyosis. *Pediatr Dermatol*. 2015;32:e151–5.
43. Maynard MT. Vitamin D in acne: A comparison with X-ray treatment. *Cal West Med*. 1938;49:127–32.
44. Lim SK, Ha JM, Lee Y, Seo YJ, Kim CD, Lee JH, et al. Comparison of vitamin D levels in patients with and without acne: A case-control study combined with a randomized controlled trial. *PLoS One*. 2016;11:e0161162.
45. Lee WJ, Choi YH, Sohn MY, Lee SJ, Kim do W. Expression of inflammatory biomarkers from cultured sebocytes was influenced by treatment with vitamin D. *Indian J Dermatol*. 2013;58:327.
46. Agak GW, Qin M, Nobe J, Kim MH, Krutzik SR, Tristan GR, et al. Propionibacterium acnes induces an IL-17 response in acne vulgaris that is regulated by vitamin A and vitamin D. *J Invest Dermatol*. 2014;134:366–73.
47. Zouboulis CC, Seltmann H, Abdel-Naser MB, Hossini AM, Menon GK, Kubba R. Effects of extracellular calcium and 1,25 dihydroxyvitamin D3 on sebaceous gland cells in vitro and in vivo. *Acta Derm Venereol*. 2017;97:313–20.
48. El-Hamid MA, El Taieb MA, Ibrahim HM, Aly SS. Vitamin D levels in acne vulgaris patients treated with oral isotretinoin. *J Cosmet Dermatol*. 2018, <http://dx.doi.org/10.1111/jocd.12503> [In press].
49. Kelly G, Sweeney CM, Fitzgerald R, ÓKeane MP, Kilbane M, Lally A, et al. Vitamin D status in hidradenitis suppurativa. *Br J Dermatol*. 2014;170:1379–80.
50. Karagiannidis I, Nikolakis G, Sabat R, Zouboulis CC. Hidradenitis suppurativa/Acne inversa: An endocrine skin disorder? *Rev Endocr Metab Disord*. 2016;17:335–41.
51. Guillet A, Brocard A, Bach Nghou K, Graveline N, Leloup AG, Ali D, et al. Verneuil's disease, innate immunity and vitamin D: A pilot study. *J Eur Acad Dermatol Venereol*. 2015;29:1347–53.
52. Karagün E, Ergin C, Baysak S, Erden G, Aktas H, Ekiz Ö. The role of serum vitamin D levels in vitiligo. *Postepy Dermatol Alergol*. 2016;33:300–2.
53. Upala S, Sanguankeo A. Low 25-hydroxyvitamin D levels are associated with vitiligo: A systematic review and meta-analysis. *Photodermatol Photoimmunol Photomed*. 2016;32:181–90.
54. Lotti T, Buggiani G, Troiano M, Assad GB, Delescluse J, de Giorgi V, et al. Targeted and combination treatment for vitiligo. Comparative evaluation of different current modalities in 458 subjects. *Dermatol Ther*. 2008;21 Suppl. 1:s20–6.
55. Parsad D, Saini R, Verma N. Combination of PUVAsol and topical calcipotriol in vitiligo. *Dermatology*. 1998;197:167–70.
56. Khurram H, AlGhamdi KM. The relationship between the serum level of vitamin D and vitiligo: A controlled study on 300 subjects. *J Cutan Med Surg*. 2016;20:139–45.
57. Monticciolo OA, Teixeira T, Chies JA, Brenol JC, Xavier RM. Vitamin D and polymorphisms of VDR gene in patients with systemic lupus erythematosus. *Clin Rheumatol*. 2012;31:1411–21.
58. Amital H, Szekanecz Z, Szucs G, Danko K, Nagy E, Csepány T, et al. Serum concentration of 25-OH vitamin D in patients with systemic lupus erythematosus (SLE) are inversely related to disease activity: Is it time to routinely supplement

- patients with SLE with vitamin D? *Ann Rheum Dis.* 2010;69:1155–7.
59. Eloi M, Horvath DV, Ortega JC, Prado MS, Andrade LE, Szejnfeld VL, et al. 25-hydroxyvitamin D serum concentration, not free and bioavailable vitamin D, is associated with disease activity in systemic lupus erythematosus patients. *PLoS One.* 2017;12:e0170323.
60. Karimzadeh H, Shirzadi M, Karimifar M. The effect of vitamin D supplementation in disease activity of systemic lupus erythematosus patients with vitamin D deficiency: A randomized clinical trial. *J Res Med Sci.* 2017;27:4.
61. Dall'Ara F, Cutolo M, Andreoli L, Tincani A, Paolino S. Vitamin D and systemic lupus erythematosus: A review of immunological and clinical aspects. *Clin Exp Rheumatol.* 2018;36:153–62.
62. Hassanilou T, Khalili L, Ghavamzadeh S, Shokri A, Payahoo L, Bishak YK. Role of vitamin D deficiency in systemic lupus erythematosus incidence and aggravation. *Auto Immun Highlights.* 2017;9:1.
63. Schweintzger NA, Gruber-Wackernagel A, Shirsath N, Quehenberger F, Obermayer-Pietsch B, Wolf P. Influence of the season on vitamin D levels and regulatory T cells in patients with polymorphic light eruption. *Photochem Photobiol Sci.* 2016;15:440–6.
64. Gruber-Wackernagel A, Obermayer-Pietsch B, Byrne SN, Wolf P. Patients with polymorphic light eruption have decreased serum levels of 25-hydroxyvitamin-D3 that increase upon 311 nm UVB photohardening. *Photochem Photobiol Sci.* 2012;11:1831–6.
65. Gruber-Wackernagel A, Bambach I, Legat FJ, Hofer A, Byrne SN, Quehenberger F, et al. Randomized double-blinded placebo-controlled intra-individual trial on topical treatment with a 1,25-dihydroxyvitamin D₃ analogue in polymorphic light eruption. *Br J Dermatol.* 2011;165:152–63.
66. Bakry OA, El Farargy SM, El Shafiee MK, Soliman A. Serum vitamin D in patients with alopecia areata. *Indian Dermatol Online J.* 2016;7:371–7.
67. Mahamid M, Abu-Elhija O, Samamra M, Mahamid A, Nseir W. Association between vitamin D levels and alopecia areata. *Isr Med Assoc J.* 2014;16:367–70.
68. Aksu Cerman A, Sarikaya Solak S, Kivanc Altunay I. Vitamin D deficiency in alopecia areata. *Br J Dermatol.* 2014;170:1299–304.
69. D'Ovidio R, Vessio M, d'Ovidio FD. Reduced level of 25-hydroxyvitamin D in chronic/relapsing alopecia areata. *Dermatoendocrinol.* 2013;5:271–3.
70. Thompson JM, Li T, Park MK, Qureshi AA, Cho E. Estimated serum vitamin D status, vitamin D intake, and risk of incident alopecia areata among US women. *Arch Dermatol Res.* 2016;308:671–6.
71. Thompson JM, Mirza MA, Park MK, Qureshi AA, Cho E. The role of micronutrients in alopecia areata: A review. *Am J Clin Dermatol.* 2017;18:663–79.
72. Kim DH, Lee JW, Kim IS, Choi SY, Lim YY, Kim HM, et al. Successful treatment of alopecia areata with topical calcipotriol. *Ann Dermatol.* 2012;24:341–4.
73. Narang T, Daroach M, Kumaran MS. Efficacy and safety of topical calcipotriol in management of alopecia areata: A pilot study. *Dermatol Ther.* 2017;30:e12464, <http://dx.doi.org/10.1111/dth.12464>.
74. Lim A, Shayan R, Varigos G. High serum vitamin D level correlates with better prognostic indicators in primary melanoma: A pilot study. *Australas J Dermatol.* 2018;59:182–7, <http://dx.doi.org/10.1111/ajd.12648>.
75. Slominski AT, Brozyna AA, Zmijewski MA, Józwicki W, Jetten AM, Mason RS, et al. Vitamin D signaling and melanoma: Role of vitamin D and its receptors in melanoma progression and management. *Lab Invest.* 2017;97:706–24.
76. Ombra MN, Paliogiannis P, Doneddu V, Sini MC, Colombino M, Rozzo C, et al. Vitamin D status and risk for malignant cutaneous melanoma: Recent advances. *Eur J Cancer Prev.* 2017;26:532–41.
77. Hernández-Ortiz S, Pérez-Ramada MD, Ortiz B, Requena C, Ribas G, Aznar E, et al. Niveles de 25-hidroxivitamina D en pacientes con melanoma y factores asociados con su insuficiencia. *Actas Dermosifiliogr.* 2016;107:758–64.
78. Orlow I, Shi Y, Kanetsky PA, Thomas NE, Luo L, Corrales-Guerrero S, et al., GEM Study Group. The interaction between vitamin D receptor polymorphisms and sun exposure around time of diagnosis influences melanoma survival. *Pigment Cell Melanoma Res.* 2018;31:287–96.
79. Newton-Bishop JA, Beswick S, Randerson-Moor J, Chang YM, Affleck P, Elliott F, et al. Serum 25-hydroxyvitamin D3 levels are associated with Breslow thickness at presentation and survival from melanoma. *J Clin Oncol.* 2009;27:5439–44.
80. Newton-Bishop JA, Davies JR, Latheef F, Randerson-Moor J, Chan M, Gascoyne J, et al. 25-hydroxyvitamin D2/D3 levels and factors associated with systemic inflammation and melanoma survival in the Leeds Melanoma Cohort. *Int J Cancer.* 2015;136:2890–9.
81. Luo L, Orlow I, Kanetsky PA, Thomas NE, Fang S, Lee JE, et al., GEM Study Group. No prognostic value added by vitamin D pathway SNPs to current prognostic system for melanoma survival. *PLoS One.* 2017;12:e0174234.
82. Paolino G, Moliterni E, Corsetti P, Didona D, Bottoni U, Calvieri S, et al. Vitamin D and melanoma: State of the art and possible therapeutic uses. *G Ital Dermatol Venerol.* 2017, <http://dx.doi.org/10.23736/S0392-0488.17.05801-1>.
83. Tang JY, Fu T, Lau C, Oh DH, Bikle DD, Asgari MM. Vitamin D in cutaneous carcinogenesis: Part II. *J Am Acad Dermatol.* 2012;67:817.e1–11.
84. Reddy KK. Vitamin D level and basal cell carcinoma, squamous cell carcinoma, and melanoma risk. *J Invest Dermatol.* 2013;133:589–92.
85. Eide MJ, Johnson DA, Jacobsen GR, Krajenta RJ, Rao DS, Lim HW, et al. Vitamin D and nonmelanoma skin cancer in a health maintenance organization cohort. *Arch Dermatol.* 2011;147:1379–84.
86. Albert B, Hahn H. Interaction of hedgehog and vitamin D signaling pathways in basal cell carcinomas. *Adv Exp Med Biol.* 2014;810:329–41.
87. Burns EM, Guroji P, Ahmad I, Nasr HM, Wang Y, Tamimi IA, et al. Association of vitamin D receptor polymorphisms with the risk of nonmelanoma skin cancer in adults. *JAMA Dermatol.* 2017;153:983–9, <http://dx.doi.org/10.1001/jamadermatol.2017.1976>.
88. Park SM, Li T, Wu S, Li WQ, Qureshi AA, Cho E. Vitamin D intake and risk of skin cancer in US women and men. *PLoS One.* 2016;11:e0160308.
89. Roux C, Briot K. Imminent fracture risk. *Osteoporos Int.* 2017;28:1765–9.
90. Priemel M, von Domarus C, Klatte TO, Kessler S, Schlie J, Meier S, et al. Bone mineralization defects and vitamin D deficiency: Histomorphometric analysis of iliac crest bone biopsies and circulating 25-hydroxyvitamin D in 675 patients. *J Bone Miner Res.* 2010;25:305–12.
91. Bischoff-Ferrari HA, Zhang Y, Kiel DP, Felson DT. Positive association between serum 25-hydroxyvitamin D level and bone density in osteoarthritis. *Arthritis Rheum.* 2005;53:821–6.
92. Reid IR, Bolland MJ, Grey A. Effects of vitamin D supplements on bone mineral density: A systematic review and meta-analysis. *Lancet.* 2014;383:146–55.

93. Bischoff-Ferrari HA, Willett WC, Orav EJ, Lips P, Meunier PJ, Lyons RA, et al. A pooled analysis of vitamin D dose requirements for fracture prevention. *N Engl J Med.* 2012;367:40–9.
94. Peris P, Martínez-Ferrer A, Monegal A, Martínez de Osaba MJ, Muxi A, Guañabens N. 25 hydroxyvitamin D serum levels influence adequate response to bisphosphonate treatment in postmenopausal osteoporosis. *Bone.* 2012;51:54–8.
95. Adami S, Giannini S, Bianchi G, Sinigaglia L, Di Munno O, Fiore CE, et al. Vitamin D status and response to treatment in postmenopausal osteoporosis. *Osteoporos Int.* 2009;20:239–44.